Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COASTAL: Zandelisib vs Standard of Care in Relapsed iNHL
NCT04745832Phase 3Terminated
- Sponsor
- MEI Pharma
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of zandelisib in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by MEI Pharma. Started Aug 2021; status: terminated.
02
Drugs
zandelisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04745832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745832.